References
- Incident Management System Ebola Epidemiology Team CDC, Guinea Interministerial Committee for Response Against the Ebola V, World Health O, et al. Update: ebola virus disease epidemic–west Africa, November 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1064–1066.
- WHO. Ebola Situation Report, 30 March 2016. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016 [cited 2016 Oct 5].
- WHO. Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa – WHO statement, 8 August 2014. http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/ [cited 2016 Oct 5].
- Meltzer MI, Atkins CY, Santibanez S, et al. Estimating the future number of cases in the Ebola epidemic–liberia and Sierra Leone, 2014–2015. MMWR Suppl. 2014;63(3):1–14.
- Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26(52):6894–6900.
- Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Suppl 3):S1075–S1081.
- Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521–531.
- Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–7304.
- Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–790.
- Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009;4(5):e5547.
- de Wit E, Marzi A, Bushmaker T, et al. Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis. 2015;21(4):702–704.
- Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11):e1000225.
- Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):e1567.
- Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32(43):5722–5729.
- Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647–1660.
- ElSherif MS, Brown C, MacKinnon-Cameron D, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017;189(24):E819–E827.
- Heppner DG Jr., Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17(8):854–866.
- Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15(10):1156–1166.
- Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376(4):330–341.
- Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518.
- Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials. 2016;13(1):49–56.
- Incident Management System Ebola Epidemiology Team CDC, Guinea Interministerial Committee for Response Against the Ebola V, World Health O, et al. Update: ebola virus disease epidemic–west Africa, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(4):109–110.
- Ebola ςa Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015;351:h3740.
- Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–866.
- Widdowson MA, Schrag SJ, Carter RJ, et al. Implementing an Ebola Vaccine Study - Sierra Leone. MMWR Suppl. 2016;65(3):98–106.
- Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis Virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215(12):1789–1798.
- Coller BG, Blue J, Das R, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017;35(35 Pt A):4465–4469.
- Bolay F A randomized controlled trial of the safety and immunogenicity of two Ebola Vaccines. Abstract 76LB. Presented at The Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle, WA, USA.
- Marzi A, Robertson SJ, Haddock E, et al. EBOLA VACCINE. VSV-EBOV Rapidly Protects Macaques against Infection with the 2014/15 Ebola Virus Outbreak Strain. Science. 2015;349(6249):739–742.
- WHO. Emergency use assessment and listing procedure (EUAL) for candidate in vitro diagnostics (IVDs) for use in the context of a public health emergency. July 7, 2015. [cited 2016 Oct 5]. Available from: http://www.who.int/medicines/news/EUAL-diagnostics_7July2015_MS.pdf
- Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survivors - final report. N Engl J Med. 2017;377(15):1428–1437.
- Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med. 2015;373(25):2448–2454.
- WHO. Ebola Outbreak, 2014–2015. [cited 2016 Oct 5]. Available from: http://www.who.int/csr/disease/ebola/en/.
- WHO. EBOLA VIRUS DISEASE Democratic Republic of Congo. External Situation Report 17 25 July 2018. [cited 18 9 15]. Available from: http://apps.who.int/iris/bitstream/handle/10665/273348/SITREP_EVD_DRC_20180725-eng.pdf?ua=1.
- WHO. Emergency preparedness, response. [cited 2016 Oct 5]. Available from: http://www.who.int/csr/research-and-development/blueprint/en/
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: general principles for the development of vaccines to protect against global infectious diseases. 2011. [cited 2016 Nov 29]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM282995.pdf
- U.S. Food and drug Administration. Emergency use authorization. 2015. [cited 2016 Nov 29]. Available from: http://www.fda.gov/EmergencyPreparedness/Counterterrorism/ucm182568.htm
- Boateng EK Overview of regulatory perspective from AVAREF representative. 2014. [cited 2016 Nov 29]. Available from: http://www.who.int/immunization/diseases/ebola/10-AVAREF_Talk.pdf
- Cavaleri M, Thomson A, Salmonson T, et al. A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola. Clin Trials. 2016;13(1):101–104.
- Krause PR, Cavaleri M, Coleman G, et al. Approaches to demonstration of Ebola virus vaccine efficacy. Lancet Infect Dis. 2015;15(6):627–629.
- Russek-Cohen E, Rubin D, Price D, et al. A US Food and Drug Administration perspective on evaluating medical products for Ebola. Clin Trials. 2016;13(1):105–109.
- Cohen J Issues continue to dog the testing of Ebola drugs and vaccines. http://www.sciencemag.org/news/2014/10/issues-continue-dog-testing-ebola-drugs-and-vaccines [cited 2016 Nov 29].
- Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384(9952):1423–1424.
- Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014;312(13):1299–1300.
- Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384(9957):1896–1899.
- Dzau VJ, Rodin J. Creating a global health risk framework. N Engl J Med. 2015;373(11):991–993.
- Roemer-Mahler A, Elbe S. The race for Ebola drugs: pharmaceuticals, security and global health governance. Third World Quarterly. 2016;37(3):487–506.
- CEPI. Coalition for epidemic preparedness innovations. [cited 2016 Nov 29]. Available from: http://cepi.net/sites/default/files/CEPI_2pager_10_Jan_17.pdf
- Rottingen JA, Gouglas D, Feinberg M, et al. New vaccines against epidemic infectious diseases. N Engl J Med. 2017;376(7):610–613.
- Sands P, Mundaca-Shah C, Dzau VJ. The neglected dimension of global security–a framework for countering infectious-disease crises. N Engl J Med. 2016;374(13):1281–1287.